Abstract
Glioblastomas are highly resistant to radiation and chemotherapy. Currently, there are no effective therapies for this type of tumor. Signaling mechanisms initiated by PDGFR and IGF-1R are important in glioblastoma, and inhibition of the signal transduction pathways initiated by these receptors could be a useful alternative strategy for glioblastoma treatment. We have studied the effects of the PDGFR inhibitor JNJ-10198409 (JNJ) and the IGF-1R inhibitor picropodophyllin (PPP) in glioblastoma cell lines as well as in primary cultures derived from patients affected by this type of tumor. JNJ and PPP treatment blocked PDGFR and IGF-1R signaling respectively and reduced Akt and Erk 1/2 phosphorylation. Both inhibitors diminished cell proliferation, inducing a G2/M block of the cell cycle. Cell death induced by JNJ was caspase-dependent, Annexin-V positive and caused PARP cleavage, especially in T98 cells, suggesting an apoptotic mechanism. However, cell death induced by PPP was not completely inhibited by caspase inhibitors in all cell lines apart from LN-229 cells, indicating a caspase-independent mechanism. Several inhibitors targeted against different cell death pathways could not block this caspase-independent component, which may be a non-programmed necrotic mechanism. Apoptotic arrays performed in T98 and LN-229 cells upon JNJ and PPP treatment revealed that procaspase 3 levels were augmented by both drugs in T98 cells and only by JNJ in LN229-cells. Furthermore, XIAP and survivin levels were much higher in LN-229 cells than in T98 cells, revealing that LN-229 cells are more susceptible to undergo caspase-independent cell death mechanisms. JNJ and PPP combination was more effective than each treatment alone.
Highlights
Malignant gliomas are cancers found frequently in the central nervous system
Western blot analyses were performed in order to determine the protein expression levels of PDGFR-α, PDGFR-β and Insulin-like growth factor 1 receptor (IGF-1R) in the glioblastoma cell lines utilized in our study
We show that IGF-1R and PDGFR inhibition are powerful strategies for combating glioblastoma
Summary
Malignant gliomas are cancers found frequently in the central nervous system. Among these tumors, the most common subtype, glioblastoma multiforme (GBM), is characterized by being very aggressive and difficult to treat [1]. Glioblastomas are very heterogeneous, have a high proliferation rate and are resistant to chemotherapy and radiation. Therapy is based mainly on surgery, radiation and chemotherapy [2]. In spite of the big advances in clinical and translational research, there are no effective therapies for glioblastoma. The first line chemotherapeutic treatment at present is the alkylating agent temozolomide [3]. There is a great need for better treatments. Transmembrane tyrosine kinase receptors play an important role in cancer
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.